Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt, Inc. reports developments as a life sciences and health-innovation platform with operating subsidiaries focused on diagnostics, precision oncology, and immune-system technologies. Company news includes updates on Ignite Proteomics, a commercial-stage precision oncology business that uses functional protein profiling to support cancer therapy selection, and Pearsanta, which is developing blood-based diagnostic tests including the Mitomic Endometriosis Test.
Recurring ADTX coverage also includes subsidiary leadership, clinical and research publications, acquisition activity, shareholder votes, reverse stock splits, Nasdaq listing matters, and other capital-structure actions tied to the company’s publicly traded common stock.
Aditxt (Nasdaq: ADTX) signed a definitive business combination agreement that values its 100%-owned subsidiary Ignite Proteomics at about $150 million. Ignite is expected to separate and list on the NYSE via a new holding company, while Aditxt remains a separate Nasdaq-listed health innovation company.
Ignite Proteomics (NASDAQ: ADTX) announced a prospective oncology registry enrolling up to 10,000 patients to pair its CLIA-certified RPPA proteomics platform with structured outcomes tracking across ADC and immunotherapy regimens.
The agreement is expected to generate about $13 million for Ignite and support future AI-enabled diagnostic and therapy-guidance tool development, with enrollment planned to begin in fall 2026.
Aditxt (NASDAQ:XRN) appointed Jeffrey M. Busch as Interim CEO effective May 31, 2026, while he continues leading subsidiary Ignite Proteomics. Busch previously founded and led an NYSE-listed healthcare real estate company to over $1 billion enterprise value and ~8.5% average dividend yield.
Aditxt plans an accelerated commercialization strategy centered on Ignite's precision oncology diagnostics platform following founder Amro Albanna’s resignation from all company and subsidiary roles.
Aditxt (NASDAQ: ADTX) approved a 1-for-27 reverse stock split of its common shares, effective at the open of trading on May 18, 2026. Post-split shares will continue trading under symbol ADTX with new CUSIP 007025869.
According to Aditxt, approximately 13,773,321 shares outstanding will consolidate to about 510,123 shares. Fractional shares will be rounded up to the next whole share. Warrants and stock options, including exercise prices, will be adjusted proportionally. The move is primarily intended to help meet Nasdaq’s minimum bid price requirement.
Aditxt (NASDAQ: ADTX) announced a Dana-Farber peer-reviewed study (published April 2026) showing Ignite Proteomics’ RPPA platform demonstrated predictive value for outcomes with trastuzumab deruxtecan (T-DXd) in metastatic breast cancer. Ignite was the only commercially available multiplex assay in the study and detected TOPO1 in some HER2-negative tumors. The assay is CLIA-certified, CAP-accredited, and listed on the Medicare Clinical Laboratory Fee Schedule under CPT PLA 0249U.
Aditxt (Nasdaq: ADTX) announced Jeff Busch as CEO of its newly acquired subsidiary Ignite Proteomics on March 19, 2026. Ignite operates a commercial-stage precision oncology platform that measures active proteins to guide cancer therapy selection and has Medicare reimbursement.
Busch, founder and former CEO of Chiron Real Estate (NYSE: XRN), will lead commercial expansion and evaluate strategic growth and financing alternatives to scale revenue and pursue sustainable profitability.
Aditxt (NASDAQ: ADTX) acquired commercial-stage precision oncology company Ignite Proteomics to expand therapy-selection and longitudinal monitoring capabilities in cancer care. Ignite operates a CLIA-certified lab, has a Medicare PLA reimbursement pathway (~$2,200/test), ongoing clinical validation with leading centers, and collaborations including an Inova project covering up to 600 tumor samples.
Transaction consideration totals 36,000 Series A-2 preferred shares with an aggregate stated value of $36.0 million.
Aditxt (NASDAQ: ADTX) will effect a 1-for-8 reverse stock split effective at the open of trading on March 9, 2026. Every eight pre-split shares will be exchanged for one post-split share, with fractional shares rounded up.
Immediately after the reverse split the company will have approximately 517,856 shares issued and outstanding and a new CUSIP 007025877. Outstanding warrants and stock options will be adjusted in line with the split. The action is intended to bring the company into compliance with Nasdaq minimum bid price requirements.
Aditxt (NASDAQ: ADTX) filed a preliminary proxy seeking shareholder approval for an employee stock purchase plan and a non-binding advisory vote to change its name to bitXbio as part of a strategic shift to a platform combining public markets, blockchain/Web3 and life sciences.
ThebitXbio strategy describes a planned Digital Asset Treasury (DAT) with a crypto reserve, a native utility token, and tokenized venture representations, but Aditxt currently holds no digital assets. The company highlighted Pearsanta’s planned IPO in 2026 (subject to market conditions) and disclosed holdings in Evofem: Series F-1 preferred stated value $26,280,000 and convertible notes $3,730,769.
Aditxt (NASDAQ: ADTX) will effect a 1-for-113 reverse stock split of its common stock, effective at the open of trading on November 3, 2025, with the post-split shares continuing to trade under the symbol ADTX.
Per the announcement, every 113 pre-split shares will be exchanged for 1 post-split share, fractional shares will be rounded up, the company will have approximately 501,401 shares issued and outstanding after the split, the CUSIP will change to 007025885, and outstanding warrants and stock options will be adjusted in line with the reverse split. The split was approved by stockholders on September 23, 2025 and is intended to bring the company into compliance with Nasdaq minimum bid price rules.